UTHR (United Therapeutics) Total Liabilities : $920 Mil (As of Dec. 2024)

View and export this data going back to 1999. Start your Free Trial

What is United Therapeutics Total Liabilities?

United Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 was $920 Mil.

United Therapeutics's quarterly Total Liabilities declined from Jun. 2024 ($1,026.00 Mil) to Sep. 2024 ($1,022.20 Mil) and declined from Sep. 2024 ($1,022.20 Mil) to Dec. 2024 ($920.00 Mil).

United Therapeutics's annual Total Liabilities declined from Dec. 2022 ($1,247.80 Mil) to Dec. 2023 ($1,182.20 Mil) and declined from Dec. 2023 ($1,182.20 Mil) to Dec. 2024 ($920.00 Mil).

United Therapeutics Total Liabilities Historical Data

The historical data trend for United Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Total Liabilities Chart

United Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

1,219.80

1,210.20

1,247.80

1,182.20

920.00

United Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,182.20	1,157.10	1,026.00	1,022.20	920.00

United Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

United Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	738.1	+	(0	+	181.9
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	920

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	7364	-	6444
	=	920

United Therapeutics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	738.1	+	(0	+	181.9
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	920

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	7364	-	6444
	=	920

United Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

UTH:Germany

Address

1000 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Executives

Michael Benkowitz	officer: President and COO	C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky	director
Nilda Mesa	director	C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Louis W Sullivan	director
Paul A Mahon	officer: EVP & General Counsel
Judy D. Olian	director	2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Richard Giltner	director	C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
James Edgemond	officer: CFO and Treasurer	1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey	director
Martine A Rothblatt	director, officer: Chief Executive Officer
Raymond Dwek	director
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Katherine J Klein	director	STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Roger Jeffs	director, officer: President and COO